Revolution Medicines CFO granted stock, options

Revolution Medicines, Inc. reported that Chief Financial Officer Anders Jack acquired new equity awards.

Rhea-AI Filing Summary

Revolution Medicines, Inc. reported that Chief Financial Officer Anders Jack acquired new equity awards. On March 1, 2026, he received a stock option covering 45,400 shares at an exercise price of $0.00 per share and a grant of 20,200 shares of common stock, both recorded as direct ownership.

The filing states that shares held include 62,538 restricted stock units. The option vests in equal monthly installments over 48 months starting March 1, 2026, so that all 45,400 option shares are fully vested and exercisable by the fourth anniversary, contingent on his continued service.

Insider Trade Summary

Grant/Award: 65,600 shares

Grant/Award 2 txns

Insider Anders Jack

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,400	$0.00	$0.00
Grant/Award	Common Stock	20,200	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 45,400 contracts (Direct); Common Stock — 128,265 shares (Direct)

Footnotes (2)

1. F1. Includes 62,538 restricted stock units.
2. F2. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did RVMD CFO Anders Jack report on this Form 4?

CFO Anders Jack reported receiving a stock option for 45,400 shares and a grant of 20,200 shares of common stock. Both awards were recorded as direct ownership and were acquired at a stated price of $0.00 per share as part of his compensation.

How many Revolution Medicines (RVMD) option shares were granted to the CFO?

The CFO was granted a stock option covering 45,400 shares of Revolution Medicines common stock. According to the filing, one forty-eighth of these option shares vests monthly starting March 1, 2026, leading to full vesting on the fourth anniversary, subject to continued service.

What is the vesting schedule for the RVMD stock option granted to the CFO?

The stock option vests over four years, with one forty-eighth of the 45,400 shares vesting each month from March 1, 2026. The filing states all shares will be fully vested and exercisable by the fourth anniversary, assuming the CFO remains in service through each vesting date.

How many RVMD common shares does the CFO hold after these transactions?

After the reported grant of 20,200 shares, the CFO holds 128,265 shares of Revolution Medicines common stock. The filing notes that these holdings include 62,538 restricted stock units, which typically convert into shares as they vest according to their separate schedules.

Were the RVMD equity awards to the CFO open-market purchases or compensation grants?

The awards were compensation-related grants, not open-market purchases. The Form 4 uses code "A" for grant, award, or other acquisition, and lists a price of $0.00 per share for both the 45,400-share option and the 20,200-share common stock award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 09:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		20,200	A	$0	128,265(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.02	03/01/2026		A		45,400		(2)	02/28/2036	Common Stock	45,400	$0	45,400	D

Explanation of Responses:

1. Includes 62,538 restricted stock units.

2. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

	/s/ Jack Anders	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.